🇺🇸 FDA
Pipeline program

LY3454738

18569

Phase 2 small_molecule terminated

Quick answer

LY3454738 for Atopic Dermatitis is a Phase 2 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).

Program details

Company
Eli Lilly and Company
Indication
Atopic Dermatitis
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials